Author

A. Franzetti-Pellanda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:statistical model· 1

Frequent Co-Authors

C. Garzoni· 3 shared A. Ceschi· 2 shared C. Saliba· 2 shared C. Silacci-Fregni· 2 shared D. Pinto· 2 shared E. Cameroni· 2 shared J. Bassi· 2 shared J. Noack· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Garzoni

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2

F. Bianchini, V. Crivelli, M. E. Abernathy, C. Guerra, M. Palus, J. Muri, H. Marcotte, A. Piralla, M. Pedotti, R. De, L. Simonelli, M. Matkovic, C. Toscano, M. Biggiogero, V. Calvaruso, , Ru

The paper identifies broadly cross-reactive neutralizing antibodies against SARS-CoV-2 variants using coldspot-guided antibody discovery.

bioRxiv · Nov 24, 2022 · PreprintImmunology

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

bioRxiv · Dec 12, 2021Immunology